Abstract
Mucositis is a side effect associated with the use of chemotherapy, and has a significant impact on the quality of life. Mucositis, by definition, refers to the inflammation of the mucosa and occurs throughout the alimentary tract from the mouth to anus. Nuclear Factor kappa B (NFκB) encompasses a family of transcription factors, which upregulate pro-inflammatory cytokines. These are recognized as key targets in developing therapeutic interventions for chemotherapy-induced mucositis, and cyclooxygenase (COX)-2 inhibition may also be beneficial in reducing the severity and duration. This review focuses on the pathobiology of chemotherapy-induced oral and gastrointestinal mucositis and recent research examining the role of agents with anti-inflammatory activity in treatment and prevention of the condition. We consider agents in clinical use as well as some others under current investigation including plant-derived and other natural medicines.
Keywords: Mucositis, chemotherapy, gastrointestinal, inflammation, anti-inflammatory, natural agents.
Current Pharmaceutical Design
Title:Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis
Volume: 24 Issue: 14
Author(s): Vaishnavi J. Mahendran, Andrea M. Stringer, Susan J. Semple, Yunmei Song and Sanjay Garg*
Affiliation:
- School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide,Australia
Keywords: Mucositis, chemotherapy, gastrointestinal, inflammation, anti-inflammatory, natural agents.
Abstract: Mucositis is a side effect associated with the use of chemotherapy, and has a significant impact on the quality of life. Mucositis, by definition, refers to the inflammation of the mucosa and occurs throughout the alimentary tract from the mouth to anus. Nuclear Factor kappa B (NFκB) encompasses a family of transcription factors, which upregulate pro-inflammatory cytokines. These are recognized as key targets in developing therapeutic interventions for chemotherapy-induced mucositis, and cyclooxygenase (COX)-2 inhibition may also be beneficial in reducing the severity and duration. This review focuses on the pathobiology of chemotherapy-induced oral and gastrointestinal mucositis and recent research examining the role of agents with anti-inflammatory activity in treatment and prevention of the condition. We consider agents in clinical use as well as some others under current investigation including plant-derived and other natural medicines.
Export Options
About this article
Cite this article as:
Mahendran J. Vaishnavi, Stringer M. Andrea, Semple J. Susan, Song Yunmei and Garg Sanjay*, Advances in the Use of Anti-inflammatory Agents to Manage Chemotherapy-induced Oral and Gastrointestinal Mucositis, Current Pharmaceutical Design 2018; 24 (14) . https://dx.doi.org/10.2174/1381612824666180409093918
DOI https://dx.doi.org/10.2174/1381612824666180409093918 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparative Analysis of Stage Specific Gene Regulation of Apicomplexan Parasites: Plasmodium falciparum and Toxoplasma gondii
Infectious Disorders - Drug Targets Regulation of Expression and Function of IDO in Human Dendritic Cells
Current Medicinal Chemistry Chlorogenic Acid Suppresses a Cell Adhesion Molecule in Experimental Autoimmune Myocarditis in Mice
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nanomedicine for Intranasal Delivery to Improve Brain Uptake
Current Drug Delivery Drug Repurposing Approaches: Existing Leads for Novel Threats and Drug Targets
Current Protein & Peptide Science Editorial [Hot Topic:Anti-Inflammatory Strategy: Old Ally or New Promise in Therapy (Guest Editor: Marcella Reale)]
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Developments in High-Yield System Expressed Vaccines and Immunotherapy
Recent Patents on Biotechnology TRP Channels: New Potential Therapeutic Approaches in CNS Neuropathies
CNS & Neurological Disorders - Drug Targets Current and Future Applications for Stem Cell Therapies in Spine Surgery
Current Stem Cell Research & Therapy Role of Cytokines in Allograft Rejection
Current Pharmaceutical Design Hyaluronidase Inhibitors: A Biological and Therapeutic Perspective
Current Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The DREAM of Pain Relief
Current Rheumatology Reviews Origins, Structures, and Bioactivities of Secondary Metabolites from Marine-derived Penicillium Fungi
Mini-Reviews in Medicinal Chemistry Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology mTOR Inhibitors (Rapamycin and its Derivatives) and Nitrogen Containing Bisphosphonates: Bi-Functional Compounds for the Treatment of Bone Tumours
Current Medicinal Chemistry Cell-Type Restricted Responses to Chronic Oxidative Stress
Current Respiratory Medicine Reviews New Ways of Detecting ADRs in Neonates and Children
Current Pharmaceutical Design Addictions and Stress: Clues for Cocaine Pharmacotherapies
Current Pharmaceutical Design Candidate Molecules that Alter the Abnormal Mucosal Immune System in Human Type 1 Diabetes
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued)